Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes

作者：Hiddo J.L. Heerspink, Allon N. Friedman, Petter Bjornstad, Daniël H. van Raalte, David Z.I. Cherney, Dachuang Cao, Luis‐Emilio García‐Pérez, Adam Stefański, Ibrahim Turfanda, Mathijs C. M. Bunck, Imane Benabbad, Ryan M. Griffin, Carolina Piras de Oliveira · 发表于：Journal of the American Society of Nephrology · 年份：2025 · DOI：10.1681/asn.0000000764 · 被引用次数：18 · 研究领域：Diet and metabolism studies

Key Points People with obesity and/or type 2 diabetes are at higher risk of progressive kidney function loss. We assessed the association of tirzepatide use with kidney function parameters in people with overweight/obesity with or without type 2 diabetes. Tirzepatide treatment was associated with urine albumin-to-creatinine reduction after 24 weeks, which was sustained through week 72, and no change in eGFR. Background Tirzepatide, a once-weekly, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, showed kidney-protective effects in people with type 2 diabetes at high cardiovascular disease risk. In this post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials, we assessed the association of tirzepatide use with kidney function parameters in people with overweight/obesity with or without type 2 diabetes. Methods In SURMOUNT-1, participants with overweight or obesity without type 2 diabetes were randomized to tirzepatide 5, 10, and 15 mg or placebo. In SURMOUNT-2, participants with type 2 diabetes were randomized to tirzepatide 10 and 15 mg or placebo. For this analysis, all tirzepatide groups were pooled in each trial. Assessments included change from baseline to week 72 for urine albumin-to-creatinine ratio (UACR) and eGFR. eGFR was assessed using creatinine-based eGFR, cystatin-C–based eGFR, and creatinine-cystatin-C–based eGFR (Cr-Cys-C-eGFR). Results In SURMOUNT-1 ( N =2539) and SURMOUNT-2 ( N =938), the median (25th–75th percentile...